Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DYN vs INBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DYN Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–2 Matrix Metrics)

DYN Overall Winner 6-Pillar Tally: DYN 5 – 0 INBX (1 Tie) Matrix Metrics: DYN 5 – 2 INBX

As of Nov 20, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DYN carries a Unified Composite Score of 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin), whereas INBX carries 53.7/100 (HOLD) at $68.97 (N/M Forward P/E, -6286.7% operating margin).

  • Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (53.7/100 HOLD vs. DYN 39.9/100 SELL), DYN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -6286.7% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: DYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DYN vs INBX
DYN NASDAQ Head-to-Head Winner
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$15.50
-3.31% 1D
Market Cap $3.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.55β · 55% Vol
Unified Composite Score
39.9 / 100 SELL
Tech 25.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.0%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $17.08 · SMA50: $16.55
INBX NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$68.97
-7.21% 1D
Market Cap $1.1B
TTM Revenue $2.0M
Forward P/E N/M
Beta / 30D Vol 2.31β · 121% Vol
Unified Composite Score
53.7 / 100 HOLD
Tech 50.0 Fund 60.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.2%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $80.80 · SMA50: $91.17

6-Pillar Scorecard Institutional Category Breakdown (DYN 5 – 0 INBX)

Columns: Metric · DYN · INBX
1. Valuation Multiples DYN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.19x N/M
EV / Revenue N/M N/M
2. Growth & Scale DYN
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.0M
Market Cap $3.0B $1.1B
3. Profitability & Quality DYN
Gross Margin N/A N/A
Operating Margin 0.0% -6286.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -74.6% -1773.6%
4. Balance Sheet & Cash Flow DYN
Cash Generation (TTM) -$569M -$133M
Cash Flow Margin N/A N/A
Net Cash / Leverage $694M Net Cash $82M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DYN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 58.2% (9th %ile) 82.3% (2nd %ile)
Put/Call OI Skew 0.06x (Call-Skewed) 0.51x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DYN (5) vs INBX (2)
Institutional Metric DYN INBX Criterion Row Edge
Market Capitalization
Scale
$3.0B $1.1B Larger Scale DYN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth DYN
Operating Margin (TTM)
Profitability
0.0% -6286.7% Higher Margin DYN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-74.6% -1773.6% Higher ROE DYN
52-Week Range Position
Momentum
11% ($14–$27) 12% ($57–$155) Stronger Trend INBX
Beta / 30D Volatility
Risk Regime
1.55β · 55% Vol 2.31β · 121% Vol Lower Realized Risk DYN
Unified Institutional Score
Composite Signal
39.9 / 100 (SELL) 53.7 / 100 (HOLD) Higher Composite INBX
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.19x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$569M ($694M Net Cash) -$133M ($82M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DYN +27.26 pp
DYN: -1.71% · INBX: -28.97%
3M Horizon INBX +6.08 pp
DYN: -40.36% · INBX: -34.28%
6M Horizon DYN +21.16 pp
DYN: -10.77% · INBX: -31.93%
1Y Horizon INBX +8.73 pp
DYN: -24.76% · INBX: -16.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs INBX. Trailing 12-month operating profitability (DYN 0.0% vs INBX -6286.7%) and valuation multiples (DYN N/M vs INBX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M
INBX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross MarginN/A
Op. Margin-6286.7%
ROE / Fwd P/E-1773.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DYN BREAKDOWN
72d in phase · OBV DISTRIBUTION
Current IV 58.2%
IV Percentile 9th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
138d in phase · OBV DISTRIBUTION
Current IV 82.3%
IV Percentile 2nd %ile
Put/Call OI Skew 0.51x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact INBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $15.87 · IV 56.7%

DYN Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,587)

Compare $1,587 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 56.7% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $16 / $17.5 Bull Call Spread

Buy 2x $16C · Sell 2x $17.5C · 30d

Net Entry $200 Debit
T+5d @ +5% Move +$24 (+12%)
Max Risk / Buffer $200 Capped
5d Edge & Liquidity 0.5x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $16 / $15 Bear Put Spread

Buy 2x $16P · Sell 2x $15P · 30d

Net Entry $136 Debit
T+5d @ -5% Drop +$22 (+16%)
Max Risk / Buffer $136 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INBX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and -6286.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DYN vs INBX Key Questions & Quantitative Answers

As of Nov 20, 2026, Dyne Therapeutics, Inc. (DYN) is the stronger overall head-to-head candidate over Inhibrx Biosciences, Inc. (INBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DYN carries a Unified Composite Score of 39.9/100 (SELL) at $15.50 (N/M Forward P/E, 0.0% operating margin), whereas INBX carries 53.7/100 (HOLD) at $68.97 (N/M Forward P/E, -6286.7% operating margin). Composite vs. Pillar Nuance: While INBX currently prints a higher short-term Unified Composite Score (53.7/100 HOLD vs. DYN 39.9/100 SELL), DYN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -6286.7% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: DYN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile INBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DYN leads the Growth & Scale pillar: DYN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INBX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (N/A gross margin, -6286.7% operating margin). On trailing 12-month operating scale, DYN generates N/A in USD-normalized revenue versus $2.0M for INBX. In operating R&D and SG&A reinvestment, DYN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INBX.

DYN screens cheaper on headline valuation multiples. DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin), whereas INBX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DYN (-74.6% ROE) versus INBX (-1773.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DYN carries 58.2% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.55β · 55% Vol realized risk). By comparison, INBX carries 82.3% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.51x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.31β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.